Overexpressed in several malignant tumours (including gastric cancer), LY6K derives peptide LY6K‐177 (RYCNLEGPPI) designed for this target, and the latter can be seen as a promising CPP in immunotherapy. The gene discussed is LY6K; the disease is cancer.